logo-loader
Lancor Scientific

Lancor Scientific on the commercial push as it advances its tumour trace product

Lancor Scientific's CEO Aamir Butt and sales director Rory Lavelle update Proactive London's Andrew Scott on developments as news broke that they've gained access to a cancer research laboratory in Austria. 

''Having access to that kind of capability means we can now make the bold claim that by the end of 2019 we'll have a device capable of multiple cancers'', Butt says.

''What we're aiming to do is make cancer detection available for everyone, everywhere'', he adds.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lancor Scientific named herein, including the promotion by the Company of Lancor Scientific in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Alchemist sees big market in China for medical cannabis sales

Alchemist (CSE: AMS) CEO Paul Mann and Vice President of Business Development, Asia Pacific Johnson Lee joined Steve Darling from Proactive Vancouver to discuss Alchemist looking for opportunities for cannabis in the emerging cannabis market.  Mann and Lee talk about what the industry...

1 day, 18 hours ago

2 min read